SCHEMBL16242011

SCHEMBL16242011

CCC(Oc1ccc(C(=O)C(C)C)nc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.51
PPARG P37231 11/20 0.42
PPARA Q07869 11/20 0.42
CYP4F2 P78329 3/20 0.39
CYP4A11 Q02928 3/20 0.39
ALDH1A1 P00352 1/20 0.38
P4HTM Q9NXG6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6112960 0.80 SMN1; SMN2 (0.48) SMN1; SMN2PPARGPPARACYP4F2CYP4A11
SCHEMBL6112957 0.80 SMN1; SMN2 (0.48) SMN1; SMN2PPARGPPARACYP4F2CYP4A11
SCHEMBL6112971 0.76 SMN1; SMN2 (0.52) SMN1; SMN2PPARGPPARACYP4F2CYP4A11
SCHEMBL20665993 0.76 DRD3 (0.44) ALDH1A1P4HTM
SCHEMBL20133266 0.75 ACACB (0.36) SMN1; SMN2
SCHEMBL20330345 0.73 ABL1 (0.37) SMN1; SMN2ALDH1A1P4HTM
SCHEMBL18592271 0.72 ABL1 (0.36) ALDH1A1P4HTM
SCHEMBL11550284 0.72 SMN1; SMN2 (0.67) SMN1; SMN2PPARGPPARA
SCHEMBL27812384 0.72 ACACB (0.44) PPARGPPARAALDH1A1P4HTM
SCHEMBL27410147 0.72 P4HTM (0.53) SMN1; SMN2ALDH1A1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725438-B2 Substituted phenylazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-08-08 US disclosed
US-9725438-B2 Substituted phenylazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-08-08 US disclosed
US-9725438-B2 Substituted phenylazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-08-08 US disclosed
EP-3009433-B1 2-PHENYL-1,3-OXAZOLE AND 5-PHENYL-1,2,4-OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES DAIICHI SANKYO CO LTD (JP) 2017-06-21 EP disclosed
EP-2805941-B1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-08-17 EP disclosed
EP-3009433-A1 2-PHENYL-1,3-OXAZOLE AND 5-PHENYL-1,2,4-OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES Daiichi Sankyo Company, Limited (JP) 2016-04-20 EP disclosed
US-20160090375-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-03-31 US disclosed
US-20160090375-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-03-31 US disclosed
US-20160090375-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-03-31 US disclosed
US-20160081993-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160081993-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160081993-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-9233958-B2 Substituted phenylazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-12 US disclosed
US-9233958-B2 Substituted phenylazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-12 US disclosed
US-9233958-B2 Substituted phenylazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-12 US disclosed
US-20140357675-A1 Substituted Phenylazole Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-04 US disclosed
US-20140357675-A1 Substituted Phenylazole Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-04 US disclosed
US-20140357675-A1 Substituted Phenylazole Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-04 US disclosed
EP-2805941-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160081993-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE IAPP, SLC5A1, GPR119 SMN1; SMN2 1928/4885PPARG 68/4885PPARA 120/4885
US-20160090375-A1 SUBSTITUTED PHENYLAZOLE DERIVATIVE IAPP, SLC5A1, GPR119 SMN1; SMN2 1928/4885PPARG 68/4885PPARA 120/4885
US-20140357675-A1 Substituted Phenylazole Derivatives IAPP, SLC5A1, GPR119 SMN1; SMN2 1910/4885PPARG 65/4885PPARA 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.